文献速递儿科与产科急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

儿童糖尿病酮症酸中毒补液速度的临床试验

Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
PubMed 文献 · N Engl J Med · 2018-01-01
一句话结论在儿童糖尿病酮症酸中毒中,静脉补液速度与氯化钠浓度均未显著影响神经系统结局。

该13中心随机对照试验采用2×2析因设计,将儿童糖尿病酮症酸中毒 episodes 随机分配至0.9%或0.45%氯化钠、快速或慢速补液四组,主要终点为治疗期间连续两次格拉斯哥昏迷评分<14分。共报告1255名儿童的1389次酮症酸中毒 episodes,48次(3.5%)评分降至<14分,12次(0.9%)出现临床明显脑损伤。各治疗组在主要终点、短期记忆、临床脑损伤发生率及恢复后记忆与IQ评分上均无显著差异,其他严重不良事件罕见且各组频率相似。

要点

  • 13中心随机对照试验纳入1255名儿童的1389次糖尿病酮症酸中毒 episodes,比较0.9%与0.45%氯化钠及快速与慢速补液。
  • 主要终点格拉斯哥昏迷评分连续两次<14分发生于48次 episodes(3.5%),临床明显脑损伤发生于12次(0.9%)。
  • 补液速度与氯化钠浓度各组间在格拉斯哥昏迷评分下降百分比、下降幅度、持续时间上均无显著差异。
  • 短期记忆测试、恢复后2至6个月记忆与IQ评分在各组间亦无显著差异。
  • 除意识状态改变外的严重不良事件罕见,且在各治疗组中发生频率相似。

适用人群与场景

  • 接受糖尿病酮症酸中毒治疗的儿童。

诊断标准与关键阈值

  • 主要终点:治疗期间连续两次格拉斯哥昏迷评分<14分(量表范围3至15分,分数越低意识状态越差)。

处置流程与药物剂量

  • 2×2析因设计随机分配至0.9%或0.45%氯化钠内容,以及快速或慢速给药速度四组之一。

研究设计与关键结果

  • 13中心随机对照试验,1255名儿童共报告1389次糖尿病酮症酸中毒 episodes。
  • 格拉斯哥昏迷评分降至<14分发生于48次 episodes(3.5%),临床明显脑损伤发生于12次(0.9%)。
  • 各治疗组在格拉斯哥昏迷评分降至<14分的 episodes 百分比、评分下降幅度、评分<14分持续时间上均无显著差异。
  • 各治疗组在短期记忆测试结果上无显著差异。
  • 各治疗组在治疗期间临床明显脑损伤发生率上无显著差异。
  • 恢复后记忆与IQ评分在各组间亦无显著差异。
  • 除意识状态改变外的严重不良事件罕见,且在各治疗组中发生频率相似。

证据类型、等级与局限

  • 证据类型:13中心随机对照试验。
  • 资助:Eunice Kennedy Shriver National Institute of Child Health and Human Development 与 Health Resources and Services Administration。
  • 试验注册:PECARN DKA FLUID,ClinicalTrials.gov编号NCT00629707。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:补液速度与氯化钠浓度均未显著影响儿童糖尿病酮症酸中毒的神经系统结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Diabetic ketoacidosis in children may cause brain injuries ranging from mild to severe. Whether intravenous fluids contribute to these injuries has been debated for decades.

METHODS: We conducted a 13-center, randomized, controlled trial that examined the effects of the rate of administration and the sodium chloride content of intravenous fluids on neurologic outcomes in children with diabetic ketoacidosis. Children were randomly assigned to one of four treatment groups in a 2-by-2 factorial design (0.9% or 0.45% sodium chloride content and rapid or slow rate of administration). The primary outcome was a decline in mental status (two consecutive Glasgow Coma Scale scores of <14, on a scale ranging from 3 to 15, with lower scores indicating worse mental status) during treatment for diabetic ketoacidosis. Secondary outcomes included clinically apparent brain injury during treatment for diabetic ketoacidosis, short-term memory during treatment for diabetic ketoacidosis, and memory and IQ 2 to 6 months after recovery from diabetic ketoacidosis.

RESULTS: A total of 1389 episodes of diabetic ketoacidosis were reported in 1255 children. The Glasgow Coma Scale score declined to less than 14 in 48 episodes (3.5%), and clinically apparent brain injury occurred in 12 episodes (0.9%). No significant differences among the treatment groups were observed with respect to the percentage of episodes in which the Glasgow Coma Scale score declined to below 14, the magnitude of decline in the Glasgow Coma Scale score, or the duration of time in which the Glasgow Coma Scale score was less than 14; with respect to the results of the tests of short-term memory; or with respect to the incidence of clinically apparent brain injury during treatment for diabetic ketoacidosis. Memory and IQ scores obtained after the children's recovery from diabetic ketoacidosis also did not differ significantly among the groups. Serious adverse events other than altered mental status were rare and occurred with similar frequency in all treatment groups.

CONCLUSIONS: Neither the rate of administration nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes in children with diabetic ketoacidosis. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Health Resources and Services Administration; PECARN DKA FLUID ClinicalTrials.gov number, NCT00629707 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Kuppermann N, Ghetti S, Schunk JE, et al. Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis. N Engl J Med. 2018. PMID: 29897851. doi:10.1056/NEJMoa1716816

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。